Pyxis Oncology shareholders approve doubling authorized shares
Alpha Vantage · Investing.com India · · AI-summarised by FinFlash
Pyxis Oncology shareholders approved an amendment doubling authorized common shares from 190 million to 380 million, effective upon filing in Delaware. The company said the increase gives it flexibility for future capital raising, a key step given negative free cash flow of $67.9 million over the past year. The vote came at a virtual special meeting of stockholders.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.